Improvement of dizocilpine-induced social recognition deficits in mice by brexpiprazole, a novel serotonin–dopamine activity modulator / Noriko Yoshimi en European Neuropsychopharmacology, Año 2015 - Vol. 25 - No.3 (Marzo)

Público ISBD [artículo]  inEuropean Neuropsychopharmacology > Año 2015 - Vol. 25 - No.3 (Marzo) . - pp. 356-364 Título : Improvement of dizocilpine-induced social recognition deficits in mice by brexpiprazole, a novel serotonin–dopamine activity modulator Tipo de documento: texto impreso Autores: Noriko Yoshimi, Autor ; Takashi Futamura, Autor ; Kenji Hashimoto, Autor Fecha de publicación: 2021 Artículo en la página: pp. 356-364 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Fármaco antipsicótico, Brexpiprazol, Dizocilpina, Reconocimiento social, Receptor 5-HT1A Resumen: Cognitive impairment, including impaired social cognition, is largely responsible for the deterioration in social life suffered by patients with psychiatric disorders, such as schizophrenia and major depressive disorder (MDD). Link: ./index.php?lvl=notice_display&id=26816 [artículo] Improvement of dizocilpine-induced social recognition deficits in mice by brexpiprazole, a novel serotonin–dopamine activity modulator [texto impreso] / Noriko Yoshimi, Autor ; Takashi Futamura, Autor ; Kenji Hashimoto, Autor . - 2021 . - pp. 356-364. Idioma : Inglés (eng) Idioma original : Inglés (eng) in European Neuropsychopharmacology > Año 2015 - Vol. 25 - No.3 (Marzo) . - pp. 356-364 Palabras clave: Fármaco antipsicótico, Brexpiprazol, Dizocilpina, Reconocimiento social, Receptor 5-HT1A Resumen: Cognitive impairment, including impaired social cognition, is largely responsible for the deterioration in social life suffered by patients with psychiatric disorders, such as schizophrenia and major depressive disorder (MDD). Link: ./index.php?lvl=notice_display&id=26816

---

1 (1 - 1 / 1)